Current stock page

Catalysts

ABVX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ABVXAbivax S.A.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 5/10
$87.58−$2.62 (−2.90%)

Latest quote

  • Momentum
    34
  • Value
    —
  • Quality
    35
  • Risk resilience
    37
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Dec 21, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 35/100

Momentum 34/100 and sentiment — before the next covered event.

Recent coverage
0 articles

Updated — · Sentiment not scored

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 34/100AIQ Edge 5/10 In Line With Peers
Beat rate
50%
4 of 8 reported periods
Average surprise
-31.9%
Across covered historical reports
Latest result
-75.3%
Sep 21, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Sep 21, 2026—-$0.98-$1.71-75.3%$799.17K$1.37M
May 22, 2026—-$1.07-$0.71+33.6%$401.13K$1.51M
Mar 23, 2026—-$1.70-$1.19+30.0%$1.8M$515.06K
Dec 15, 2025—-$0.79-$2.47-214.3%$1.35M$2.4M
Sep 8, 2025—-$0.90-$0.86+4.4%$1.39M$1.33M
Jun 2, 2025—-$0.76-$0.97-28.3%$3.35M$1.16M
Mar 24, 2025—-$1.59-$1.68-5.8%$2.83M$6.37M
Nov 14, 2024—-$0.70-$0.70+0.3%$3.59M—

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
12
Buy
12-month analyst target
$141.33
+61.38% versus current price
Based on 12 analyst observations. Targets are estimates, not predictions.
Low target
$118.00
+34.73% vs latest price
Average target
$141.33
+61.38% vs latest price
High target
$155.00
+76.98% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateDec 21, 2026

Next known earnings or reporting date.

EPS estimate-$0.92

Current analyst expectation for the upcoming report.

Revenue estimate$922.55K

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score34

Where event reaction would show up first.

AIQ score35/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
12
Average target
$141.33
Target upside
61.38%
Target range
$118.00 - $155.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

No recent articles have a scored sentiment label.
Positive
0
Neutral
0
Negative
0

No recent company-specific news is available.

Open full news and sentiment

ABVX Catalysts FAQ

What are the next catalysts for ABVX stock?

ABVX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ABVX stock?

Upcoming events that could move ABVX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ABVX's next earnings report affect the stock?

ABVX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ABVX stock higher?

ABVX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ABVX stock?

ABVX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.